Day One Biopharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $14.35
- Today's High:
- $15.07
- Open Price:
- $14.35
- 52W Low:
- $6.51
- 52W High:
- $28.35
- Prev. Close:
- $14.29
- Volume:
- 869240
Company Statistics
- Market Cap.:
- $1.03 billion
- Book Value:
- 4.083
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -34.88%
- Return on Equity TTM:
- -56.01%
Company Profile
Day One Biopharmaceuticals Inc had its IPO on 2021-05-27 under the ticker symbol DAWN.
The company operates in the Healthcare sector and Biotechnology industry. Day One Biopharmaceuticals Inc has a staff strength of 125 employees.
Stock update
Shares of Day One Biopharmaceuticals Inc opened at $14.35 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $14.35 - $15.07, and closed at $14.74.
This is a +3.15% increase from the previous day's closing price.
A total volume of 869,240 shares were traded at the close of the day’s session.
In the last one week, shares of Day One Biopharmaceuticals Inc have increased by +5.51%.
Day One Biopharmaceuticals Inc's Key Ratios
Day One Biopharmaceuticals Inc has a market cap of $1.03 billion, indicating a price to book ratio of 4.1528 and a price to sales ratio of 0.
In the last 12-months Day One Biopharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-164952992. The EBITDA ratio measures Day One Biopharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Day One Biopharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -34.88% with a return of equity of -56.01%.
In Q1, Day One Biopharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Day One Biopharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Day One Biopharmaceuticals Inc’s profitability.
Day One Biopharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -9.0239. Its price to sales ratio in the trailing 12-months stood at 0.
Day One Biopharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $323.56 million
- Total Liabilities
- $22.85 million
- Operating Cash Flow
- $-11193000.00
- Capital Expenditure
- $26000
- Dividend Payout Ratio
- 0%
Day One Biopharmaceuticals Inc ended 2024 with $323.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $323.56 million while shareholder equity stood at $-312061000.00.
Day One Biopharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $22.85 million in other current liabilities, 7000.00 in common stock, $-312061000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.27 million and cash and short-term investments were $318.18 million. The company’s total short-term debt was $417,000 while long-term debt stood at $0.
Day One Biopharmaceuticals Inc’s total current assets stands at $322.39 million while long-term investments were $0 and short-term investments were $268.91 million. Its net receivables were $0 compared to accounts payable of $4.66 million and inventory worth $0.
In 2024, Day One Biopharmaceuticals Inc's operating cash flow was $-11193000.00 while its capital expenditure stood at $26000.
Comparatively, Day One Biopharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $14.74
- 52-Week High
- $28.35
- 52-Week Low
- $6.51
- Analyst Target Price
- $39.56
Day One Biopharmaceuticals Inc stock is currently trading at $14.74 per share. It touched a 52-week high of $28.35 and a 52-week low of $28.35. Analysts tracking the stock have a 12-month average target price of $39.56.
Its 50-day moving average was $12.97 and 200-day moving average was $16.05 The short ratio stood at 10.21 indicating a short percent outstanding of 0%.
Around 2928.4% of the company’s stock are held by insiders while 8230.3% are held by institutions.
Frequently Asked Questions About Day One Biopharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.